Health Care & Life Sciences » Biotechnology | Human Stem Cells Institute PJS

Human Stem Cells Institute PJS | Cash Flow

Fiscal year is January-December. All values RUB Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
27,388.00
160.00
62,525.00
130,968.00
109,975.00
18,243
Depreciation, Depletion & Amortization
22,502.00
25,002.00
26,195.00
23,992.00
40,460.00
29,652
Other Funds
-
75,000.00
36.00
-
-
59,326
Funds from Operations
43,937.00
30,176.00
328.00
138,807.00
96,894.00
35,149
Changes in Working Capital
22,653.00
1,571.00
5,441.00
163,395.00
43,291.00
45,487
Net Operating Cash Flow
66,590.00
31,747.00
5,113.00
24,588.00
53,603.00
10,338
Capital Expenditures
34,504.00
32,854.00
19,300.00
66,935.00
212,818.00
Purchase/Sale of Investments
9,432.00
4,864.00
28,924.00
3,919.00
238.00
Net Investing Cash Flow
51,546.00
37,718.00
36,435.00
62,092.00
212,857.00
Cash Dividends Paid - Total
-
-
-
21,259.00
-
Issuance/Reduction of Debt, Net
23,595.00
16,353.00
11,821.00
294,656.00
89,000.00
Net Financing Cash Flow
23,595.00
58,647.00
11,857.00
273,397.00
88,900.00
Net Change in Cash
8,551.00
52,676.00
19,465.00
234,784.00
178,769.00
Free Cash Flow
32,086.00
1,107.00
14,187.00
42,347.00
266,421.00
Deferred Taxes & Investment Tax Credit
-
-
-
18,746.00
-
35,586
Other Sources
5,963.00
-
13,111.00
11,681.00
5,142.00
Change in Capital Stock
-
-
-
-
100.00
Exchange Rate Effect
-
-
-
1,109.00
1,209.00
Other Uses
13,573.00
-
1,322.00
10,757.00
5,419.00

About Human Stem Cells Institute PJS

View Profile
Address
18/1, Olimpiyskiy Avenue
Moscow MC 129110
Russian Federation
Employees -
Website http://www.hsci.ru
Updated 07/08/2019
Human Stem Cells Institute OJSC engages in the discovery, research, development, and marketing of proprietary products and services in the field of regenerative medicine, medical genetics, bio-insurance, gene therapy, and biopharmaceutics. Its research and development involves gemacell and cryocell; service for personal regeneration of bone and of gum; nucleostim; preventive treatment program for primary immunodeficiency diseases; human artificial chromosome; development of drugs using histone proteins; and development of drugs using a novel technology employing polysialic acid. The company was founded by Isaev Alexandrovich Artur on November 3, 2003 and is headquartered in Moscow, Russia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.